About
Company Profile
Management Team
Honors Course
Vision & Mission
Chengdu Biostar
Synthetic Biology
R&D
Clinical Recruitment
Pipeline
Partnering
Product
Utidelone
Medical consultation and Drug Safety Hotline
News
Company News
Career
Core Value
Corporate Benefit
Contact
Career
Contact
CN
菜单
搜索
Index
About
Company Profile
Management Team
Honors Course
Vision & Mission
Chengdu Biostar
Synthetic Biology
R&D
Clinical Recruitment
Pipeline
Partnering
Product
Utidelone
Medical consultation and Drug Safety Hotline
Contact
Career
Contact
新闻动态
Company News
全部
全部
2021
2020
2019
2024-03-28
73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis
2024-03-21
100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer
2023-06-16
FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer
2023-06-12
Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)—The World's First Oral Epothilone Anti-Cancer Drug